One Genomics and CiRA Foundation Announce Strategic Research Collaboration to Advance Precision Genome Engineering
Emerging AI-Driven De-Aging Company Partners with Leading iPS Cell Manufacturing and Research Foundation

KYOTO, JAPAN and SAN FRANCISCO, CA - [January, 2026] - the CiRA Foundation today announced a collaborative research agreement with One Genomics, an emerging AI-driven genomics and de-aging company, to advance precision genome engineering technologies. One Genomics was co-founded by Harvard Professor George Church alongside former Harvard and MIT research fellows and alumni.

Despite rapid progress in the field, conventional genome engineering technologies continue to face critical challenges. In addition to off-target mutations and bystander effects, current CRISPR-based approaches generally lack the ability to fine-tune outcomes. These constraints restrict the precision, safety, and reliability required for advanced cellular engineering, particularly in sensitive human cell systems, and remain a key bottleneck to broader adoption.

Through this collaboration, One Genomics will contribute its proprietary high-precision, fine-tunable CRISPR design platform, including its Safeguard approach, while the CiRA Foundation will apply these technologies in human iPS cells, drawing on its world-leading expertise in regenerative medicine to improve engineering performance across relevant cellular contexts. Together, the parties aim to advance genome engineering technologies that enable greater precision, controllability, and reliability for cellular and clinical applications.

About One Genomics

One Genomics is an AI-driven de-aging company building foundational technologies for cellular reprogramming and systemic age reversal, guided by a vision to make aging optional. The company was cofounded by MIT-trained AI entrepreneur Diana Luan; George Church, Ph.D., Professor at Harvard Medical School, world-renowned geneticist, and serial biotechnology entrepreneur; and former Harvard research fellows Masaki Kawamata, Ph.D., and Motoshi Hayano, Ph.D.
The team is building frontier AI virtual cell models to simulate how human cells and biological systems age and rejuvenate, alongside high-precision, fine-tunable genome engineering platforms for programmable cellular reprogramming. Together, these capabilities underpin the development of genetic and epigenetic age-reversal interventions that modulate aging processes at the cellular and systemic level, while naturally extending to other genome-guided applications beyond aging such as genetic disease treatment.

Investor and Partnership Inquiries
　contact*onegenomics.co (Please change * to @)

About CiRA Foundation

CiRA Foundation is a public interest corporation that started as an offshoot of the Center for iPS Cell Research and Application (CiRA), Kyoto University, in April 2020. Guided by the philosophy of providing top-tier iPS cell technologies at affordable prices, the CiRA Foundation engages in iPS manufacturing, quality control, and storage. In addition, CiRA Foundation is actively advancing research and development aimed at automating iPS cell manufacturing, further contributing to the practical realization of regenerative medicine.

CiRA Foundation Research Inquiries
　media*cira-foundation.or.jp (Please change * to @)